Cerenome, Inc. has finished enrolling patients in its Phase 2 trial of REYOBIQ, a targeted radiotherapeutic for recurrent glioblastoma. Interim data showed a 63% improvement in median survival compared to standard care, with patients living 13 months versus 8 months historically. The trial uses convection-enhanced delivery to bypass the blood-brain barrier and deliver radiation directly to tumors. Topline results are expected by mid-2027, after which Cerenome will meet with the FDA to discuss next steps.
Cerenome's Phase 2 trial enrollment completion for REYOBIQ in recurrent glioblastoma provides context for health-sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 95 rose and 47 fell. Notable movers include AMGN at USD 468.17 with a 3.62% increase and 82% buy order activity, VRTX at USD 547.98 up 3.45%, and INO at USD 0.96 up 3.38%. Typical hold times range from 43 to 122 days.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
